Comments on "Abiraterone acetate plus prednisolone for metastatic patients starting hormone therapy: 5-year follow-up results from the STAMPEDE randomised trial (NCT00268476)"

Int J Cancer. 2022 Dec 15;151(12):2291-2292. doi: 10.1002/ijc.34246. Epub 2022 Sep 5.
No abstract available

Publication types

  • Randomized Controlled Trial
  • Letter
  • Comment

MeSH terms

  • Abiraterone Acetate* / therapeutic use
  • Androgen Antagonists / therapeutic use
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Follow-Up Studies
  • Hormones
  • Humans
  • Male
  • Prednisolone / therapeutic use
  • Prednisone / therapeutic use
  • Prostatic Neoplasms, Castration-Resistant* / pathology
  • Treatment Outcome

Substances

  • Abiraterone Acetate
  • Prednisolone
  • Androgen Antagonists
  • Hormones
  • Prednisone